Periodic Versus Continuous IV Iron Supplementation in HD Patients

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to compare the efficacy of two regimens of intravenous iron sucrose [continuous (in every hemodialysis session) versus intermittent (every 1-4 weeks)] on the response of rHuEPO in the maintenance phase of its administration in hemodialysis patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Papageorgiou General Hospital
• Treatments: Ferric Compounds; Ferric Oxide, Saccharated; Iron

Criteria

Inclusion Criteria:

• Constant rHu-EPO and iron dose for at least 2 months before starting the study

• Hemoglobin ≥ 8,5g/dl and <12,5 g/dl

• Ferritin < 1000 mg/dl

• TSAT < 50%

• CRP < 5 mg/dl

Exclusion Criteria:

• Malignant tumor disease

• Oral iron supplementation

• Active bleeding issues

• Surgical intervention within the last 8 weeks before study inclusion